46 results about "Myeloma cell" patented technology

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

The invention discloses an anti-phenacetin monoclonal antibody hybridoma cell strain AD, a preparation method and application thereof, and relates to the technical field of food safety immunodetection. The monoclonal antibody hybridoma cell strain is named monoclonal cell strain AD and the number CGMCC19681. The Phe-BA obtained by the hydrolysis of the reaction product of the phenacetin metabolite acetaminophen and ethyl 4-bromobutyrate is used as the hapten, and the hapten is coupled with the carrier protein to prepare the immunogen Phe-BA-BSA. After the mice were immunized with the immunogen Phe-BA-BSA, they were fused with myeloma cells by PEG method, screened by indirect competitive enzyme-linked immunosorbent assay and subcloned five times to obtain hybridoma cell lines. The monoclonal antibody secreted by the cell line can be made into a phenacetin detection kit, which has good affinity and detection sensitivity for phenacetin, and can be used for immunodetection of phenacetin residues in food.

The present application relates to the field of biotechnology and in vitro diagnosis, and relates to a monoclonal antibody of eosinophil peroxidase and application thereof. The antibody of the present application is mainly used for detecting the content of eosinophil peroxidase by western blot. The monoclonal antibody of eosinophil peroxidase of the present application is prepared by immunizing Balb / c mice with recombinant eosinophil peroxidase as an immunogen, then fusing the spleen with myeloma cells NS1, and screening and purifying. The prepared monoclonal antibody of eosinophil peroxidase specifically recognizes the linear epitope of eosinophil peroxidase.

The present invention provides a monoclonal antibody that recognizes a recombinant EGF-CRM197 vaccine and a preparation method thereof. Based on the research and development and preparation of a recombinant EGF-CRM197 vaccine, the present invention further immunizes mice with the recombinant EGF-CRM197 vaccine, fuses the mouse spleen cells with mouse myeloma cells, screens and produces a hybridoma cell line of specific monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine, and obtains the antibody sequence after sequencing. After the hybridoma cells are cultured in mice, monoclonal antibodies that recognize the recombinant EGF-CRM197 vaccine can be prepared in vitro by methods such as chromatography purification. The present invention can be used for the release potency detection of the recombinant EGF-CRM197 vaccine and for evaluating the immune efficacy after immunization with the recombinant EGF-CRM197 vaccine.

The invention discloses a series of colchicine deuterated derivatives for resisting multiple myeloma, which can effectively inhibit proliferation of multiple myeloma cells by improving the metabolic effect of colchicine in the multiple myeloma cells and overcome the defect of large toxic and side effects of metabolism of original drugs. According to the series of colchicine deuterated derivatives capable of resisting multiple myeloma, colchicine is used as a raw material, two reactions of demethylation and deuterated methyl are sequentially performed to obtain a target compound, the reaction steps are few, the reaction conditions are mild, the operability is high, and the efficiency is high.

The invention discloses a method for inducing cell copper death based on GK921 and application of the GK921, and relates to the technical field of biological medicine. The invention discloses a brand new function of inducing copper death by a known compound GK921 for the first time, and provides a brand new strategy for solving the problems of drug resistance and relapse of multiple myeloma. According to the method, target cells are treated with an effective amount of GK921, expression of copper ion transporter ATP7A in the cells is specifically reduced, copper ions are accumulated, and then typical copper death events such as iron-sulfur cluster protein reduction and DLAT protein oligomerization are caused. Experiments show that the GK921 can efficiently inhibit the activity of multiple myeloma cell lines and primary cells, and the IC50 value and the low toxicity to normal cells show excellent selectivity. On the basis, GK921 can be used for preparing a pharmaceutical composition for inducing copper death, and particularly has an important application prospect in treatment of multiple myeloma.

Provided are human therapeutic compositions including a compound comprising a plurality of fused polycyclic moieties and a linker moiety. In certain embodiments, the compound is a reaction product of an aldehyde and a harmine component. The compositions exhibit anti-cancer properties, particularly against lymphoma, leukemia, pancreatic, endometrial, ovarian, gastric, breast, renal, cervical, head and neck, and myeloma cell lines.

The application relates to the technical field of monoclonal antibodies, and specifically discloses an anti-p-Tau181 antibody and a preparation method and application thereof. The preparation method of the anti-p-Tau181 antibody comprises the following steps: taking a p-Tau181 polypeptide IPAKTPPAPK(pT)PPSSGEPPK as an immunogen, injecting the immunogen into experimental animals to perform an immune response, and obtaining spleen lymphocytes of the experimental animals; taking myeloma cells and the spleen lymphocytes to perform mixed culture to obtain fusion cells; culturing the fusion cells, obtaining supernatant, and performing ELISA detection; the polypeptide used for detection is the p-Tau181 polypeptide; taking the hybridoma cell strain with a positive detection result to perform counter screening with a p-Tau217 polypeptide, a p-Tau231 polypeptide and t-tau protein; screening a positive clone which has a reaction to the p-Tau181 polypeptide and has no reaction to the p-Tau217 polypeptide, the p-Tau231 polypeptide and the t-tau protein; performing multiple cloning screening; obtaining a hybridoma cell strain which can secrete antibodies every time; and taking the antibodies secreted by the hybridoma cell strain as the anti-p-Tau181 antibody. The anti-p-Tau181 antibody can be specifically combined with the p-Tau181, and thus can be used for detecting Alzheimer's disease.

The application provides an abnormal prothrombin detection kit and application thereof, and relates to the technical field of in-vitro detection.The application provides a kit for abnormal prothrombin detection, which comprises an abnormal prothrombin antibody, wherein the abnormal prothrombin antibody is derived from a hybridoma cell strain 7E8-4-4-1 of fusion of myeloma cells and mouse B cells, and the hybridoma cell strain 7E8-4-4-1 is preserved in the China General Microbiological Culture Collection Center on October 28, 2025, with a preservation number of CGMCC No.46709.The kit has a large detection range, a small lower limit of detection and high accuracy, and has great application potential in the detection of abnormal prothrombin.

The invention discloses an application of a CaMKII-gamma inhibitor serving as a bortezomib-resistant multiple myeloma treatment medicine. On the basis of si-RNA, cell proliferation activity can be inhibited by down-regulating expression of CaMKII-gamma in bortezomib-resistant multiple myeloma U266.BR cells and KMS11. BR cells, a small molecule compound rucotinib capable of effectively inhibiting activity of CaMKII-gamma kinase is obtained through high-throughput screening, growth of multiple myeloma U266 cells and KMS11 cells can be obviously inhibited, and the activity of the rucotinib can be effectively inhibited. The compound has an obvious inhibition effect on the growth of bortezomib-resistant multiple myeloma U266.BR cells and KMS11. BR cells, also has an obvious inhibition effect on the growth of U266.BR transplantation tumors, and shows a good tumor inhibition effect as a potential medicine for treating multiple myeloma and bortezomib-resistant multiple myeloma.

The invention provides an anti-medetomidine monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. Medetomidine is used for immunizing a Balb / c mouse, splenocytes of the mouse are fused with myeloma cells, hybridoma cells with high specificity are obtained through specific high-throughput screening, a large amount of mouse ascites is obtained through culture and re-immunization, and the mouse ascites with high specificity is obtained. And the medetomidine monoclonal antibody with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting medetomidine. The anti-medetomidine monoclonal antibody disclosed by the invention can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody is proved to have good specific binding capacity.

The invention relates to the technical field of nano antibodies, in particular to an anti-FcRH5 nano antibody and application thereof. The invention provides an anti-FcRH5 nano antibody with high affinity and specificity, and the anti-FcRH5 nano antibody is based on a single-domain heavy chain variable region structure from camelidae and has the advantages of small molecular weight, high stability, strong tissue penetrability, easiness in engineering modification and the like. The nano antibody specifically recognizes and is combined with a high-expression and stable-expression target spot on the surface of a multiple myeloma cell through a complementary determining region of the nano antibody. The nano antibody disclosed by the invention can be used as a core recognition element for constructing various treatment or diagnosis tools such as chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates or immunodetection probes and the like. According to the technical scheme, the technical problem that an anti-FcRH5 antibody with high quality and definite functionality is lacked in the prior art can be solved. The nano antibody provided by the invention has remarkable clinical transformation and industrialization advantages, and promotes multiple myeloma treatment to multi-target collaborative iteration.

The invention provides an anti-trihexylol monoclonal antibody as well as application and a product thereof, and relates to the technical field of biology. The method comprises the following steps: immunizing a Balb / c mouse by using trihexylamine, fusing splenocytes of the mouse with myeloma cells, carrying out specific high-throughput screening to obtain hybridoma cells with high specificity, and carrying out culture and re-immunization to obtain a large amount of mouse ascites. And the monoclonal antibody resisting the trihexylamine with high purity, high sensitivity and high specificity is obtained through multi-step separation and purification, so that a required raw material is provided for developing an immune test strip for detecting the trihexylamine. Through verification, the monoclonal antibody for resisting the trihexylamine disclosed by the invention has good specific binding capacity.

The invention provides application of a c-Myc G4 targeting small molecule drug in preparation of a drug for treating multiple myeloma, and belongs to the technical field of multiple myeloma. The pharmaceutical composition for treating multiple myeloma provided by the invention takes a compound shown as a formula Y502-2304 or a pharmaceutically acceptable salt thereof as an active ingredient or a main active ingredient, and is supplemented with a pharmaceutically acceptable carrier. In multiple myeloma, the compound Y502-2304 regulates apoptosis and cycle progress of cells by stabilizing the c-Myc G4 structure, promotes death of myeloma cells, can be used as a drug for treating multiple myeloma, and provides a new thought for research and development of drugs for resisting multiple myeloma. # imgabs0 #

This invention provides a monoclonal antibody against the VP2 protein of a mandarin fish two-segmented RNA virus, its preparation method, and its application. The VP2 protein was obtained by expression and purification using recombinant plasmids. Mice were immunized three times, and mice with the highest serum titer were selected for intraperitoneal booster immunization against VP2 protein. Mouse spleen cells and SP2 / 0 myeloma cells were fused, and hybridoma cell lines secreting VP2 protein antibodies were screened. These cells were then subcloned to obtain four stable hybridoma cell lines secreting anti-VP2 protein antibodies, and their heavy and light chain variable region sequences were determined. Mice were injected intraperitoneally with Freund's incomplete adjuvant, followed by the injection of the hybridoma cell lines. Ascites fluid was collected from the mice, extracted, purified, and used to obtain the monoclonal antibody against the VP2 protein. Using these four monoclonal antibodies, three highly conserved and specific antigenic epitopes of the VP2 protein of the mandarin fish two-segmented RNA virus were screened and identified. This invention provides support for establishing specific serological methods for mandarin fish two-segmented RNA viruses and for further research on the biological function and clinical diagnosis of VP2.

A blocking monoclonal antibody screening method based on a porcine PD-1 / PD-L1 monoclonal antibody and a heterologous Fc fusion protein comprises the following steps: (a) preparing a porcine PD-1 or PD-L1 extracellular region recombinant protein; (b) immunizing mice by using the recombinant protein to obtain immune spleen cells; (c) fusing the immune spleen cells with myeloma cells to obtain hybridoma cells; (d) screening and subcloning a hybridoma cell strain capable of secreting an anti-porcine PD-1 or PD-L1 antibody; (e) preparing a porcine PD-L1-rabbit Fc fusion protein; and (f) evaluating the blocking effect of the monoclonal antibody on PD-1 / PD-L1 binding by using the PD-L1-rabbit Fc fusion protein through flow cytometry.

This invention relates to the field of traditional Chinese medicine composition technology, and particularly to an oral traditional Chinese medicine composition for treating multiple myeloma and its preparation method. It comprises the following components in parts by weight: Bupleurum chinense 10-12 parts, Cyperus rotundus 8-10 parts, Curcuma longa 8-10 parts, Oroxylum indicum 5-6 parts, Angelica sinensis 8-10 parts, Paeonia lactiflora 8-10 parts, Atractylodes macrocephala 10-12 parts, Poria cocos 10-12 parts, Codonopsis pilosula 8-10 parts, Glycyrrhiza uralensis (processed) 5-6 parts, Agrimonia pilosa 6-8 parts, Bambusa textilis 8-10 parts, Mentha haplocalyx 4-6 parts, and Zingiber officinale 4-6 parts. The composition provided by this invention not only directly inhibits the growth of myeloma cells, but also comprehensively improves the survival prognosis of model animals by regulating liver and spleen function, improving immune status, and reducing phlegm-heat and blood stasis. It provides a stable, safe, and easily promoted oral traditional Chinese medicine preparation for the clinical treatment of multiple myeloma.

The present invention relates to a pharmaceutical composition for preventing or treating cancer, the pharmaceutical composition containing CD4+ CTL as an active ingredient. The CD4+ CTL according to the present invention performs a cytotoxic function of directly attacking and killing myeloma cells, thereby extending the progression-free survival of transplant-ineligible myeloma patients, and thus can contribute to increasing the survival rate of the patients. In addition, by using NKG2D+ CD4+ CTL as a biomarker for predicting the prognosis of myeloma patients, it is possible to analyze the CD4+ CTL status of individual patients and thereby establish customized treatment strategies. In addition, by increasing the cytotoxicity of NKG2D+ CD4+ CTL through a specific cytokine treatment, it is possible to more effectively prevent or treat cancer.

The application discloses a myeloma microscopic cell image cancer cell counting method and belongs to the technical field of medical image processing. In order to solve the problem of realizing automatic and accurate counting of myeloma cells, the application collects myeloma multi-channel microscopic image data for adaptive preprocessing, fuses noise suppression and convolution enhancement, obtains pixel gray value of the preprocessed myeloma multi-channel microscopic image, then carries out rough segmentation of cancer cells based on edge constraint to obtain a rough segmentation mask of the image, then carries out deep feature extraction to obtain the deep feature of the pixel of the preprocessed myeloma multi-channel microscopic image, then calculates the average deep feature of the cells, then combines Bayesian prior correction to calculate the probability of the cancer cells through MLP deep modeling, and finally, the application verifies the cancer cell counting result through correlation coefficient calibration combined with clinical prior constraint to obtain the final myeloma cancer cell counting result. The application provides technical support for standardization and normalization of myeloma diagnosis.

The application provides a kind of sandwich detection testosterone monoclonal antibody and its preparation method and application, comprising: step S1, preparation testosterone-3-(O-carboxymethyl) oxime, and it is activated;After activation, take testosterone antibody P2G1, according to proportion, drop the activated testosterone-3-(O-carboxymethyl) oxime is reacted to prepare immunogen;Step S2, based on the prepared immunogen, immunization animal;Step S3, the spleen cell of immunization animal and myeloma cell are fused into hybridoma cell, and the real hybridoma cell is selected;Step S4, antibody is separated and purified from the screened hybridoma cell.The application provides a kind of preparation method of raw material and reagent for testosterone sandwich method detection, solves the problem that the sensitivity of small molecule compound testosterone competition method reagent is insufficient, detection range is narrow, specificity is poor, provides a new thought and method for the rapid, accurate detection of testosterone.

The invention discloses an interferon regulatory factor 4 (IRF4) inhibitor as shown in a formula (1) and a preparation method thereof, and a target product is prepared by taking dinorhydrin as a raw material through reactions such as TBS protection, 4, 4-dimethylation, TBS protection removal, oxidation, esterification, reduction, iodination, cyano substitution, Wittig, hydrolysis, esterification, amidation, condensation and the like. The invention further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM), and further discloses an application of the IRF4 inhibitor in the aspect of treating multiple myeloma (MM). The compound can selectively inhibit the multiplication capacity of IRF4 high-expression myeloma cells, and has a good application prospect in treatment of IRF4 high-expression tumors such as multiple myeloma and lymphoma.

The present application relates to the field of biotechnology and in vitro diagnosis, in particular to a monoclonal antibody against eosinophil peroxidase and its application. The antibody of the present application can directly and specifically capture the eosinophil peroxidase with enzymatic activity, and is used in biological research and clinical diagnosis of eosinophils. The monoclonal antibody against eosinophil peroxidase of the present application is prepared by immunizing Balb / c mice with recombinant eosinophil peroxidase as an immunogen, then fusing the spleen with myeloma cells NS1, and screening and purifying. The prepared monoclonal antibody against eosinophil peroxidase specifically recognizes the epitope of eosinophil peroxidase.

The invention belongs to but is not limited to the technical field of biological medicines, and discloses application of a ferroptosis inducer in preparation of a medicine for treating t (4; 14) application in a positive multiple myeloma medicine; the combination of the CD38 monoclonal antibody and the RSL3 is at t (4; 14) a synergistic effect in positive multiple myeloma cells; the action target of the combination of the CD38 monoclonal antibody and the RSL3 medicine is GPX4. The CD38 monoclonal antibody is combined with RSL3 to induce t (4; and 14) positive multiple myeloma cell apoptosis. The CD38 monoclonal antibody is combined with RSL3 to induce t (4; and 14) positive multiple myeloma cell ferroptosis.

The present application relates to the technical field of biological medicine, and particularly relates to an anti-Aβ 42 Monoclonal antibody, preparation method and application. The present application adopts Aβ 42 protein of human origin as an immunogen to immunize BALB / c mice, extracts B lymphocytes of the spleen of the mice after successful immunization, fuses the B lymphocytes with mouse myeloma cells SP2 / 0 through cell fusion technology, and obtains hybridoma cell strains stably secreting anti-Aβ 42 monoclonal antibody after three rounds of subclone screening, so as to obtain anti-Aβ 42 monoclonal antibody; the anti-Aβ 42 monoclonal antibody can specifically combine with Aβ 42 protein, and can be used for immunological detection, has a broad market prospect, and can have important clinical significance for further development of biological monitoring technology and therapeutic drugs taking Aβ 42 as a target.

The invention discloses an anti-p53R175H / HLA-A 02: 01 monoclonal antibody, a hybridoma cell strain S2-C33 for preparing the monoclonal antibody as well as a preparation method and application of the monoclonal antibody. The preparation method of the hybridoma cell strain comprises the following steps: immunizing a BALB / c mouse by taking human p53R175H / HLA-A 02: 01 recombinant protein as an immunogen to prepare an immunized mouse; taking splenocytes of the immunized mouse, and fusing the splenocytes with the SP2 / 0 myeloma cells to prepare fusion cells; screening monoclonal antibody positive fusion cells capable of secreting a compound specifically combined with p53R175H / HLA-A 02: 01 from the fusion cells, wherein the monoclonal antibody positive fusion cells are the hybridoma cell strain. The monoclonal antibody secreted by the hybridoma cell strain can be specifically combined with p53R175H / HLA-A 02: 01 presented on the surface of cancer cells, and the specificity is relatively high.

The application provides a kind of anti-hepatitis B HBcAg monoclonal antibody and its application and product, it is related to the field of biotechnology.The application uses HBcAg to immunize Balb / c mouse, takes mouse spleen cell and fuses with myeloma cell, and obtains hybridoma cell with high specificity by specific high-throughput screening, obtains a large number of mouse ascites by culture and re-immunization, and then obtains high-purity, high-sensitivity and high-specificity anti-HBcAg monoclonal antibody by multi-step separation and purification, which provides the required raw material for developing HBcAg detection immunostrip.The anti-HBcAg monoclonal antibody of the application can be used for immunological detection such as immunoblotting and immunofluorescence, and the obtained antibody has good specific binding capacity.

The application discloses a kind of screening and anti-myeloma application of targeting c-Maf small molecule inhibitor, especially provide the application of sorafenib or glimepiride in preparation anti-myeloma drug.Aspect.The application discloses a kind of method for screening targeting c-Maf small molecule inhibitor, it includes the steps based on molecular virtual screening docking.It is found that potential compound glimepiride and sorafenib can inhibit the activity of c-Maf by the method of the application through virtual screening, molecular dynamics (MD) simulation, molecular mechanics and MM / GBSA free energy calculation and experimental analysis, both can induce the cycle stagnation and cell apoptosis of myeloma cell.The method of the application can screen more targeting c-Maf small molecule inhibitor, it is also helpful to further structure optimization based on sorafenib and glimepiride in the future, and design c-Maf small molecule inhibitor with better activity.

This invention provides a benzothiadiazine compound that inhibits histone deacetylases, its preparation method, and its applications. The general structural formula is shown in Formula (I), or an isomer thereof, or a pharmaceutically acceptable salt, ester, or prodrug thereof. The benzothiadiazine compound of this invention has a novel structure and, as an inhibitor of histone deacetylases HDAC6 and HDAC1, can effectively inhibit the proliferation of K562 (human chronic myeloid leukemia cells) and NCI-H929 (human myeloma cells). It exhibits low cytotoxicity to normal cells and low potential cardiac risk, and holds promise as a highly effective and low-toxicity antitumor therapeutic agent.

The application of mitoxantrone in inducing IRF4 protein degradation through autophagy-lysosome pathway belongs to the field of biological medicine. Mitoxantrone can specifically bind to IRF4 protein and significantly reduce the level of IRF4 protein. Mitoxantrone mainly binds to the DNA binding domain of IRF4, shortens the half-life of IRF4 protein, and promotes its degradation through the autophagy-lysosome pathway rather than the proteasome pathway. Mitoxantrone can interact with IRF4 protein and autophagy receptor p62 at the same time, promote the formation of IRF4 and p62 complex, enhance the ubiquitination modification of IRF4 and recruit it to the autophagy degradation pathway, thereby playing the role of molecular glue. Mitoxantrone treatment can inhibit the transcriptional activation function mediated by IRF4, down-regulate the expression of its downstream target genes, inhibit the proliferation of multiple myeloma cells and tumor growth, and provide a new technical approach for the development of anti-tumor drugs targeting transcription factors.

The invention discloses an anti-Taq enzyme monoclonal antibody, a preparation method thereof and an application of the anti-Taq enzyme monoclonal antibody in hot start PCR (Polymerase Chain Reaction), the method comprises the following steps: S1, immunizing an animal: selecting a mouse, emulsifying the mouse with a wild recombinant Taq enzyme protein as an antigen and a Freund's adjuvant, then performing subcutaneous injection, immunizing for 2-6 times, and measuring serum titer at an interval of 1-4 weeks; s2, cell fusion: fusing spleen cells of the mouse with the highest titer with NS-1 myeloma cells, and screening hybridoma cells; s3, screening and cloning: screening positive clone secreting an anti-Taq enzyme antibody, and obtaining a stable cell strain through 3-4 times of subcloning; and S4, antibody purification: purifying the IgG antibody in the ascites or cell supernatant to obtain the anti-Taq enzyme monoclonal antibody. The anti-Taq enzyme monoclonal antibody provided by the invention has the characteristics of high specificity, high sensitivity, good stability, simplicity and convenience in operation and the like, and has a wide application prospect.